Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement.

2022-06

Enjeti, Anoop K

Agarwal, Rishu

Blombery, Piers

Chee, Lynette

Chua, Chong Chyn

Grigg, Andrew P

Hamad, Nada

Iland, Harry

Lane, Steven

Perkins, Andrew

Singhal, Deepak

Tate, Courtney

Tiong, Ing Soo

Ross, David M

Myelodysplasia

NGS

consensus

gene panel

myeloproliferative neoplasms

Journal Article

0000-0002-2162-3288

0000-0001-5743-3171

10.1016/j.pathol.2022.03.002

This review aims to provide an expert consensus statement to address the role of gene-panel testing in the diagnosis, prognosis and management of adult myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes (MDS/MPN) in Australia. This consensus statement was developed by an expert group, actively involved in gene panel testing in the area of MDS/MPN in Australia. This work was led by the chairs of the MDS (A/Prof A. Enjeti) and MPN (A/Prof D. Ross) working parties of the Australasian Leukaemia and Lymphoma Group (ALLG). The authors were selected after an expression of interest process on the basis of active laboratory involvement in gene panel testing, a specific demonstrated interest in MDS/MPN and/or publication record in this field. The authors were then allocated sections for literature review to identify the specific genes of interest for each MDS/MPN entity. At least two authors reviewed each section and an overarching diagnostic algorithm was developed by a consensus amongst all authors.

link

Pathology 2022; 54(4): 389-398

Pathology